The Fentanyl Story the Wires Tell About the Mafia, and the One They Don't

In an analysis published by The Conversation on Friday, a writer takes on a theory that has circulated widely in foreign coverage of Italian organised crime: that Italy's mafias, wary of a drug that kills its own customers and draws police attention, have deliberately kept fentanyl out of Europe. The analysis argues this does not fit what is known about drug markets or about mafias, and that Europe's comparatively low fentanyl numbers are better explained by very little demand.

The figures it cites set the scale. Fentanyl and its derivatives were linked to around 210 drug-induced deaths in 2024 across 16 countries that reported data, up from about 130 in 2023, and most of that rise may involve medicines rather than illicitly made fentanyl. In Italy, the analysis says, the government's latest report on addiction counted only five fentanyl-related deaths in 2025.

The explanation offered is historical rather than cinematic. The United States had an aggressive prescription wave from the late 1990s, with painkillers such as OxyContin widely handed out and their addictive potential played down; when access was tightened in the 2010s, that dependence moved to the illicit market, first heroin and then fentanyl. Europe, the analysis says, never had an equivalent prescription wave, and heroin never went away.

The analysis notes that heroin remains Europe's most commonly used illicit opioid, according to the EU Drugs Agency, and that most of it has historically come from Afghanistan, entering Europe through the Balkans. That route matters to anyone reporting the south: the Balkan corridor runs to the Adriatic and then across to Italy's southern ports, and Naples has been one of the country's principal entry points for illicit goods for as long as foreign correspondents have written about the Camorra.

It is important to be precise about what this piece is. It is an opinion analysis, not a report of an event, and it does not describe any seizure, arrest or operation in Campania. What it offers is an argument about how drug markets actually work, and the argument has a local application even without a local incident: if demand, not prohibition by traffickers, governs what arrives, then the future of synthetic opioids in the Mezzogiorno depends on consumption patterns and on how opioids are prescribed, not on the decisions of any criminal organisation.

The analysis also touches on nitazenes, another class of potent synthetic opioids that it says have driven recent peaks in deaths in several countries. That is a warning that applies across Europe, and it is a reminder that the fentanyl question is narrower than the synthetic-opioid question as a whole.

The Conversation's framing is a corrective to a familiar habit in foreign coverage of the south, in which organised crime is treated as an all-powerful actor whose choices explain everything from drug supply to refuse collection. The analysis does not dispute that Italy's mafias are serious enterprises; it disputes that they are the reason fentanyl has not taken hold here. The difference matters, because a policy built on the cinematic version — more pressure on traffickers — would be aimed at the wrong target, while one built on the demand version would look at prescribing and at treatment.

For Campania the practical stake is treatment capacity and surveillance. The wire gives no Campanian figures on opioid use, prescriptions or overdose, and this dispatch will not supply any. What can be said is that the region sits on the corridor the analysis describes, and that if the argument is right, the defences that matter are public-health ones rather than the ones the crime pages usually describe.